SNP arrays of BT474 Latpatinib and/or Trastuzumab resistant cell lines for copy number analysis.
Ontology highlight
ABSTRACT: Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but de novo and acquired resistance commonly occur. The purpose of this experiment was to investigate the somatic alterations found in Lapatinib and/or Trastuzumab resistant cells lines.
ORGANISM(S): Homo sapiens
PROVIDER: GSE83608 | GEO | 2019/06/21
REPOSITORIES: GEO
ACCESS DATA